menu
    • menu
    [{"orgOrder":0,"company":"YAKULT HONSHA CO LTD","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"TAS-118","moa":"Dihydrofolate reductase\/Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"YAKULT HONSHA CO LTD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YAKULT HONSHA CO LTD \/ YAKULT HONSHA CO LTD","highestDevelopmentStatusID":"10","companyTruncated":"YAKULT HONSHA CO LTD \/ YAKULT HONSHA CO LTD"},{"orgOrder":0,"company":"YAKULT HONSHA CO LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Resminostat","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"YAKULT HONSHA CO LTD","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YAKULT HONSHA CO LTD \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"YAKULT HONSHA CO LTD \/ Undisclosed"},{"orgOrder":0,"company":"YAKULT HONSHA CO LTD","sponsor":"Japan Aerospace Exploration Agency","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Probiotic","year":"2015","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"YAKULT HONSHA CO LTD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YAKULT HONSHA CO LTD \/ Japan Aerospace Exploration Agency","highestDevelopmentStatusID":"1","companyTruncated":"YAKULT HONSHA CO LTD \/ Japan Aerospace Exploration Agency"},{"orgOrder":0,"company":"YAKULT HONSHA CO LTD","sponsor":"YAKULT HONSHA CO LTD","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"MEXICO","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Fermented Milk","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"YAKULT HONSHA CO LTD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YAKULT HONSHA CO LTD \/ YAKULT HONSHA CO LTD","highestDevelopmentStatusID":"1","companyTruncated":"YAKULT HONSHA CO LTD \/ YAKULT HONSHA CO LTD"},{"orgOrder":0,"company":"YAKULT HONSHA CO LTD","sponsor":"YAKULT HONSHA CO LTD","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"Fermented Milk","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"YAKULT HONSHA CO LTD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YAKULT HONSHA CO LTD \/ YAKULT HONSHA CO LTD","highestDevelopmentStatusID":"8","companyTruncated":"YAKULT HONSHA CO LTD \/ YAKULT HONSHA CO LTD"},{"orgOrder":0,"company":"YAKULT HONSHA CO LTD","sponsor":"YAKULT HONSHA CO LTD","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"4'-Galactooligosaccharide","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"YAKULT HONSHA CO LTD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YAKULT HONSHA CO LTD \/ YAKULT HONSHA CO LTD","highestDevelopmentStatusID":"1","companyTruncated":"YAKULT HONSHA CO LTD \/ YAKULT HONSHA CO LTD"},{"orgOrder":0,"company":"YAKULT HONSHA CO LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Lactobacillus Casei Shirota","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"YAKULT HONSHA CO LTD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YAKULT HONSHA CO LTD \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"YAKULT HONSHA CO LTD \/ Undisclosed"},{"orgOrder":0,"company":"YAKULT HONSHA CO LTD","sponsor":"Bach Mai Hospital | Vietnam National University","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Casei Strain Shirota Fermented Milk","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"YAKULT HONSHA CO LTD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YAKULT HONSHA CO LTD \/ Bach Mai Hospital | Vietnam National University","highestDevelopmentStatusID":"1","companyTruncated":"YAKULT HONSHA CO LTD \/ Bach Mai Hospital | Vietnam National University"},{"orgOrder":0,"company":"YAKULT HONSHA CO LTD","sponsor":"YAKULT HONSHA CO LTD","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"TAIWAN","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Yakult","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"YAKULT HONSHA CO LTD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YAKULT HONSHA CO LTD \/ YAKULT HONSHA CO LTD","highestDevelopmentStatusID":"1","companyTruncated":"YAKULT HONSHA CO LTD \/ YAKULT HONSHA CO LTD"},{"orgOrder":0,"company":"YAKULT HONSHA CO LTD","sponsor":"YAKULT HONSHA CO LTD","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Yakult","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"YAKULT HONSHA CO LTD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YAKULT HONSHA CO LTD \/ YAKULT HONSHA CO LTD","highestDevelopmentStatusID":"1","companyTruncated":"YAKULT HONSHA CO LTD \/ YAKULT HONSHA CO LTD"},{"orgOrder":0,"company":"YAKULT HONSHA CO LTD","sponsor":"Endang Sutriswati Rahayu","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Yakult","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"YAKULT HONSHA CO LTD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YAKULT HONSHA CO LTD \/ Endang Sutriswati Rahayu","highestDevelopmentStatusID":"1","companyTruncated":"YAKULT HONSHA CO LTD \/ Endang Sutriswati Rahayu"}]

    Find Clinical Drug Pipeline Developments & Deals by YAKULT HONSHA CO LTD

    Menu

    YAKULT HONSHA CO LTD

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            YAKULT HONSHA CO LTD

                            Japan arrow
                            AAPS
                            Not Confirmed

                            YAKULT HONSHA CO LTD

                            Japan arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 4'-Galactooligosaccharide

                            Therapeutic Area : Endocrinology

                            Study Phase : Undisclosed

                            Recipient : University of Aberdeen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of a Sugar Replacement on Blood Glucose Levels in Healthy Adults

                            Details : Galactooligosaccharide is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Hyperglycemia.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            December 03, 2024

                            Lead Product(s) : 4'-Galactooligosaccharide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Undisclosed

                            Recipient : University of Aberdeen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            YAKULT HONSHA CO LTD

                            Japan arrow
                            AAPS
                            Not Confirmed

                            YAKULT HONSHA CO LTD

                            Japan arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fermented Milk

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Recipient : University of Guadalajara

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of Lacticaseibacillus Paracasei Strain Shirota on Clinical Manifestation of Functional Constipation i...

                            Details : Fermented Milk is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Constipation.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            May 29, 2024

                            Lead Product(s) : Fermented Milk

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Recipient : University of Guadalajara

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            YAKULT HONSHA CO LTD

                            Japan arrow
                            AAPS
                            Not Confirmed

                            YAKULT HONSHA CO LTD

                            Japan arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lactobacillus Casei Strain Shirota Fermented Milk

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Sponsor : Bach Mai Hospital | Vietnam National University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lactobacillus Casei Strain Shirota Fermented Milk for Alleviating Hard Stools in Vietnam

                            Details : Lactobacillus Casei Strain Shirota Fermented Milk is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Constipation.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            August 09, 2023

                            Lead Product(s) : Lactobacillus Casei Strain Shirota Fermented Milk

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Sponsor : Bach Mai Hospital | Vietnam National University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            YAKULT HONSHA CO LTD

                            Japan arrow
                            AAPS
                            Not Confirmed

                            YAKULT HONSHA CO LTD

                            Japan arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Yakult

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : Endang Sutriswati Rahayu

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effects of Yakult Ingestion in Residents and Staffs at Indonesian Elderly Houses

                            Details : Yakult is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            April 04, 2022

                            Lead Product(s) : Yakult

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : Endang Sutriswati Rahayu

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            YAKULT HONSHA CO LTD

                            Japan arrow
                            AAPS
                            Not Confirmed

                            YAKULT HONSHA CO LTD

                            Japan arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Yakult

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Undisclosed

                            Recipient : Taipei Medical University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Fermented Milk Containing Lactobacillus Casei Strain Shirota in Sarcopenia Elderly

                            Details : Yakult is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Sarcopenia.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            August 02, 2021

                            Lead Product(s) : Yakult

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Undisclosed

                            Recipient : Taipei Medical University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            YAKULT HONSHA CO LTD

                            Japan arrow
                            AAPS
                            Not Confirmed

                            YAKULT HONSHA CO LTD

                            Japan arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Yakult

                            Therapeutic Area : Endocrinology

                            Study Phase : Undisclosed

                            Recipient : Loughborough University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Yakult Ingestion on Diet-induced Insulin Resistance in Humans

                            Details : Yakult is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Insulin Resistance.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            January 31, 2017

                            Lead Product(s) : Yakult

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Undisclosed

                            Recipient : Loughborough University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            YAKULT HONSHA CO LTD

                            Japan arrow
                            AAPS
                            Not Confirmed

                            YAKULT HONSHA CO LTD

                            Japan arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Probiotic

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : Japan Aerospace Exploration Agency

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Probiotics on Immune Function and Intestinal Microbiota in Astronauts Under Closed Microgravity Environment

                            Details : This is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            December 01, 2015

                            Lead Product(s) : Probiotic

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : Japan Aerospace Exploration Agency

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            YAKULT HONSHA CO LTD

                            Japan arrow
                            AAPS
                            Not Confirmed

                            YAKULT HONSHA CO LTD

                            Japan arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Resminostat

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma ...

                            Details : Resminostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Hepatocellular.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 27, 2015

                            Lead Product(s) : Resminostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            YAKULT HONSHA CO LTD

                            Japan arrow
                            AAPS
                            Not Confirmed

                            YAKULT HONSHA CO LTD

                            Japan arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TAS-118

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Taiho Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer

                            Details : TAS-118 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Stomach Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 23, 2014

                            Lead Product(s) : TAS-118

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Taiho Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            YAKULT HONSHA CO LTD

                            Japan arrow
                            AAPS
                            Not Confirmed

                            YAKULT HONSHA CO LTD

                            Japan arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fermented Milk

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : University of São Paulo General Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Once a Day Use of Lactobacillus Casei Shirota on HIV-infected Patients Infected Patients

                            Details : Fermented Milk is a Dietary Supplement drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of HIV Infections.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            May 23, 2014

                            Lead Product(s) : Fermented Milk

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : University of São Paulo General Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth